Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
05 janv. 2021 08h15 HE
|
Radius Health Inc.
Agreement incorporates TYMLOS® and abaloparatide-TDConsideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royaltiesKey first step in...
Radius Health Announces Change to its Board of Directors
04 janv. 2021 16h30 HE
|
Radius Health Inc.
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the...
Radius Health, Inc. Provides Business Update
15 déc. 2020 09h00 HE
|
Radius Health Inc.
Continued growth in net new patients for the month of November 2020Company is on-track for record quarter in net revenue for TYMLOS-SCResearch Agreement reached with MGH in October 2020Hired Head of...
Radius Health, Inc.: Third Quarter 2020 Operating Results
05 nov. 2020 08h00 HE
|
Radius Health Inc.
TYMLOS® U.S. net sales of $50 million with 8% year-over-year growth; Total Revenues of $78 millionQ3 commercial pivot to focus on high risk fracture segment is gaining traction: Net New U.S. Patients...
Radius Health, Inc.: Progress Since May 2020
21 oct. 2020 08h15 HE
|
Radius Health Inc.
Completed enrollment in 3 pivotal clinical trials; multiple data read outs in Q4 2021Released meaningful abaloparatide histomorphometry data at recent ASBMR meetingCompleted two business development...
Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020
20 oct. 2020 16h15 HE
|
Radius Health Inc.
WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company...
Peter A. Schwartzman Joins Radius Health, Inc.
06 oct. 2020 16h30 HE
|
Radius Health Inc.
WALTHAM, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in...
Radius Health Divests RAD 140 Program to Ellipses Pharma
01 oct. 2020 08h45 HE
|
Radius Health Inc.
Business development step enables molecule to move forwardProgram progression will be at no financial risk to RadiusReinforces Radius’ focus on execution of core business WALTHAM, Mass., Oct. 01,...
Radius Health & Menarini Group Provide Elacestrant Update
24 sept. 2020 16h15 HE
|
Radius Health Inc.; Menarini Group
Target enrollment milestone reached in the Phase 3 EMERALD studyLife cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 24,...
Radius Health Provides Business Update
24 sept. 2020 08h15 HE
|
Radius Health Inc.
Organizational Change within Finance FunctionCreates Capital, Strategy & Transactions Group WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”)...